1. 1645PAnalysis of programmed death-ligand 1 (PD-L1) expression, transforming growth factor (TGF)-β gene expression signatures (GES) and tumor-infiltrating immune cells (IC) in hepatocellular carcinoma (HCC): Rationale for targeting PD-L1- and TGF-β. (18th September 2017) Authors: Zhang, Y.; Naughton, B.J.; Rolfe, P.A.; Frick-Krieger, E.; Dussault, I.; Terracciano, L.; Ihling, C. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma. (September 2015) Authors: Qin, S.; Lim, H.Y.; Ryoo, B.Y.; Li, C.; Xiong, H.; Ihling, C.; Cheng, A.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC. (September 2015) Authors: Soo, R.A.; Kim, D.W.; Yang, J.C.H.; Stammberger, U.; Xiong, H.; Ihling, C.; Wu, Y.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗